MaxCyte Operating Cycle Over Time
| MXCT Stock | USD 0.87 0.04 4.49% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out MaxCyte Performance and MaxCyte Correlation. Is there potential for Health Care Equipment & Supplies market expansion? Will MaxCyte introduce new products? Factors like these will boost the valuation of MaxCyte. Expected growth trajectory for MaxCyte significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about MaxCyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.43) | Revenue Per Share | Quarterly Revenue Growth (0.16) | Return On Assets | Return On Equity |
Understanding MaxCyte requires distinguishing between market price and book value, where the latter reflects MaxCyte's accounting equity. The concept of intrinsic value—what MaxCyte's is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push MaxCyte's price substantially above or below its fundamental value.
Understanding that MaxCyte's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether MaxCyte represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, MaxCyte's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Cycle Analysis
Compare MaxCyte and related stocks such as Profound Medical Corp, TriSalus Life Sciences, and Anteris Technologies Operating Cycle Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PROF | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 605 | 507 | 1 K | 960 | 879 | 765 | 1.1 K | 1.3 K | 822 | 740 | 639 |
| TLSI | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 454 | 284 | 427 | 423 | 381 | 318 |
| AVR | 137 | 137 | 137 | 137 | 137 | 137 | 137 | 137 | 137 | 137 | 137 | 167 | 217 | 333 | 182 | 164 | 166 |
| LNSR | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 150 | 217 | 434 | 195 | 343 | 309 | 195 | 176 | 211 |
| OWLT | 123 | 123 | 123 | 123 | 123 | 123 | 123 | 123 | 123 | 123 | 124 | 211 | 231 | 170 | 156 | 140 | 135 |
| CATX | 125 | 100 | 109 | 113 | 118 | 72.6038 | 85.7107 | 120 | 103 | 129 | 112 | 119 | 164 | 299 | 299 | 269 | 283 |
| PRE | 145 | 145 | 145 | 145 | 145 | 145 | 145 | 145 | 145 | 145 | 172 | 1.6 K | 1.4 K | 177 | 224 | 202 | 192 |
| ARMP | 96.6176 | 352 | 352 | 8.9846 | 89.2421 | 96.0526 | (577) | 249 | 249 | 249 | 249 | 244 | 128 | 271 | 52.4855 | 47.24 | 56.11 |
| NNOX | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 700 | 98.5723 | 107 | 83.2834 | 95.78 | 90.99 |
| SGMO | 99.5455 | 44.2146 | (70.8356) | (324) | (215) | 24.4371 | 96.5693 | 28.8118 | 20.6258 | 134 | 19.329 | 20.9766 | 14.6657 | 8.4233 | 29.0358 | 33.39 | 47.43 |
MaxCyte and related stocks such as Profound Medical Corp, TriSalus Life Sciences, and Anteris Technologies Operating Cycle description
My Equities
My Current Equities and Potential Positions
| MaxCyte | MXCT |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | 9713 Key West |
| Exchange | NASDAQ Exchange |
USD 0.8691
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.